Is this Diabetes Drug Class Poised for Disruption?
The Motley Fool's health care show "Market Checkup" focuses this week on diabetes, one of America's growing health care concerns. There are 2 versions of this chonic disease -- the more prevalent being type 2 diabetes, which makes up about 95% of all cases. Because of that overwhelming patient population, type 2 diabetes receives the majority of attention from big pharma companies.
Diabetes is no small problem. In 2010, one in 10 adults has diabetes, and more troubling, more than one in four senior citizens, making it the seventh leading cause of death. There are 2 million new cases in America per year, leading analysts to project spending on diabetes to approach $60 billion in just five years. And this isn't just an American problem; 370 million suffer from diabetes around the world.
In this video, health care analysts David Williamson and Max Macaluso discuss one of the prominent diabetes drug classes, highlighting both the major players and whether a new drug from Eli Lilly will disrupt the current standard of care.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.
The article Is this Diabetes Drug Class Poised for Disruption? originally appeared on Fool.com.David Williamson owns shares of Eli Lilly. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.